



03-17-04

PHA 2004 (3167/12/US)  
PATENT

1614  
-  
4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1614  
Serial No. 09/843,132  
Filed April 25, 2001  
Confirmation No. 8349  
For ANTINEOPLASTIC COMBINATION THERAPY IN THE TREATMENT OF  
CANCER

March 16, 2004

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

\* A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Supplemental Information Disclosure Statement. The Commissioner

03/18/2004 HDEMESSI 00000018 09843132


01 FC:1806

180.00 DP

PHA 2004 (3167/12/US)  
PATENT

is hereby authorized to charge any under payment or credit any  
over payment to Deposit Account No. 19-1345.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KJD/msc


\*Enclosures

Express Mail Label No. EV 416453101 US

PTO/SB/08A

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/843,132
Filing Date	April 25, 2001
Confirmation Number	8349
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Rebecca Cook

Sheet 1 of 2 Attorney Docket No. PHA 2004 (3167/12/US)

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	44.	6,077,850		Carter et al.	06-20-2000
	45.	6,087,392		Reiter	07-11-2000
	46.	6,110,964		Robinson	08-29-2000
	47.	6,114,361		Robinson et al.	09-05-2000
	48.	6,156,798		Reiter	12-05-2000
	49.	6,214,870	B1	McClure et al.	04-10-2001
	50.	6,277,878	B1	Nakao et al.	08-21-2001
	51.	6,294,558	B1	Ando et al.	09-25-2001
	52.	6,303,628	B1	Nakao et al.	10-16-2001

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	53.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
	54.	EP	1 088 550	A1	Pfizer Products Inc.	04-04-2001	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

***Complete if Known***

Application Number	09/843,132
Filing Date	April 25, 2001
Confirmation Number	8349
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Rebecca Cook

Sheet **2** of **2** Attorney Docket No. **PHA 2004 (3167/12/US)**

	55.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	
	56.	EP	1 104 760	A1	Pfizer Products Inc.	06-06-2001	
	57.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
	58.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
	59.	WO	97/20824	A1	Agouron Pharmaceuticals, Inc.	06-12-1997	
	60.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
	61.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
	62.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
	63.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999	
	64.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
	65.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
	66.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
	67.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
	68.	WO	01/40216	A1	Pfizer Products Inc.	06-07-2001	


**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	69.	TRIFAN, O.C., et al., Cyclooxygenase-2 Inhibition with Celecoxib Enhances Antitumor Efficacy and Reduces Diarrhea Side Effect of CPT-11, Cancer Research, Oct. 15, 2002, pp. 5778-84, Vol. 62, No. 20	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..



## FEE TRANSMITTAL

Application Number 09/843,132  
Filing Date April 25, 2001  
Confirmation No. 8349  
Inventor(s) John P. McKearn et al.  
Attorney Docket Number PHA 2004 (3167/12/US)

Art Unit 1614

### METHOD OF PAYMENT

1.  The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
  - The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
  - Applicant claims small entity status.
2.  Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

### FEE CALCULATION

1.  BASIC FILING FEE Subtotal (1) \$ \_\_\_\_\_  
(Type: \_\_\_\_\_)

2.  EXTRA CLAIM FEES Subtotal (2) \$ \_\_\_\_\_  
Total Claims \_\_\_\_\_  
Independent Claims \_\_\_\_\_  
Multiple Dependent Claims \_\_\_\_\_

3.  ADDITIONAL FEES Subtotal (3) \$ 180.00

Surcharge - late filing fee or oath  
 Surcharge - late provisional filing fee or cover sheet  
 Extension for reply within \_\_\_\_\_ month  
 Notice of Appeal  
 Filing a Brief in Support of an appeal  
 Request for ex parte Reexamination  
 Petitions to the Commissioner  
 Submission of Information Disclosure Statement  
 Recording each patent assignment per property  
 Request for Continued Examination  
 Other: \_\_\_\_\_

TOTAL AMOUNT OF PAYMENT \$ 180.00

Kathryn J. Doty, Reg. No. 40,593

March 16, 2004

Date

KJD/CDS/cms

Express Mail Label No. EV 416453101 US